Although further investigation is required to elucidate the mechanism underlying FTD and anti-VEGFR2 antibody treatment efficacy for tumors in detail, this study shows that FTD-based treatment potentially improves clinical outcomes. This evidence concerns the gene KDR and frontotemporal dementia.